COVID-19 and the role of cytokines in this disease

被引:77
作者
Hasanvand, Amin [1 ]
机构
[1] Lorestan Univ Med Sci, Fac Med, Dept Physiol & Pharmacol, Khorramabad, Iran
关键词
COVID-19; Cytokines; Inflammatory response; INNATE LYMPHOID-CELLS; HIV PROTEASE INHIBITOR; GROWTH-FACTOR-BETA; T-CELLS; INFLAMMATORY CYTOKINES; GENE-EXPRESSION; TNF RECEPTOR; TGF-BETA; INTERLEUKIN-7; ACTIVATION;
D O I
10.1007/s10787-022-00992-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Studies have shown that SARS-CoV-2 has the ability to activate and mature proinflammatory cytokines in the body. Cytokine markers are a group of polypeptide signalling molecules that can induce and regulate many cellular biological processes by stimulating cell receptors at the surface. SARS-CoV-2 has been shown to be associated with activation of innate immunity, and an increase in neutrophils, mononuclear phagocytes, and natural killer cells has been observed, as well as a decrease in T cells including CD4+ and CD8. It is noteworthy that during the SARS-CoV-2 infection, an increase in the secretion or production of IL-6 and IL-8 is seen in COVID-19 patients along with a decrease in CD4+ and CD8+ and T cells in general. SARS-CoV-2 has been shown to significantly increase Th2, Th1/Th17 cells and antibody production in the body of patients with COVID-19. Specific immune profiles of SARS-CoV-2 infection can lead to secondary infections and dysfunction of various organs in the body. It has been shown that Interleukins (such as IL-1, IL-4, IL-6, IL-7, IL-10, IL-12, IL-17, and IL-18), IFN-gamma, TNF-alpha,TGF-beta and NF-kappa B play major roles in the body's inflammatory response to SARS-CoV-2 infection. The most important goal of this review is to study the role of inflammatory cytokines in COVID-19.
引用
收藏
页码:789 / 798
页数:10
相关论文
共 145 条
  • [91] How Low Cholesterol Is Good for Anti-viral Immunity
    O'Neill, Luke A. J.
    [J]. CELL, 2015, 163 (07) : 1572 - 1574
  • [92] Anti-inflammatory cytokines
    Opal, SM
    DePalo, VA
    [J]. CHEST, 2000, 117 (04) : 1162 - 1172
  • [93] COVID-19: a case for inhibiting IL-17?
    Pacha, Omar
    Sallman, Mary Alice
    Evans, Scott E.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) : 345 - 346
  • [94] Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines:: A novel mechanism for maximizing IL-7-dependent T cell survival
    Park, JH
    Yu, Q
    Erman, B
    Appelbaum, JS
    Montoya-Durango, D
    Grimes, JL
    Singer, A
    [J]. IMMUNITY, 2004, 21 (02) : 289 - 302
  • [95] Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
    Pelaia, Corrado
    Calabrese, Cecilia
    Garofalo, Eugenio
    Bruni, Andrea
    Vatrella, Alessandro
    Pelaia, Girolamo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 16
  • [96] Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
    Perrone, Francesco
    Piccirillo, Maria Carmela
    Ascierto, Paolo Antonio
    Salvarani, Carlo
    Parrella, Roberto
    Marata, Anna Maria
    Popoli, Patrizia
    Ferraris, Laurenzia
    Marrocco-Trischitta, Massimiliano M.
    Ripamonti, Diego
    Binda, Francesca
    Bonfanti, Paolo
    Squillace, Nicola
    Castelli, Francesco
    Muiesan, Maria Lorenza
    Lichtner, Miriam
    Calzetti, Carlo
    Salerno, Nicola Duccio
    Atripaldi, Luigi
    Cascella, Marco
    Costantini, Massimo
    Dolci, Giovanni
    Facciolongo, Nicola Cosimo
    Fraganza, Fiorentino
    Massari, Marco
    Montesarchio, Vincenzo
    Mussini, Cristina
    Negri, Emanuele Alberto
    Botti, Gerardo
    Cardone, Claudia
    Gargiulo, Piera
    Gravina, Adriano
    Schettino, Clorinda
    Arenare, Laura
    Chiodini, Paolo
    Gallo, Ciro
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [97] In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
    Petrone, Linda
    Petruccioli, Elisa
    Alonzi, Tonino
    Vanini, Valentina
    Cuzzi, Gilda
    Fard, Saeid Najafi
    Castilletti, Concetta
    Palmieri, Fabrizio
    Gualano, Gina
    Vittozzi, Pietro
    Nicastri, Emanuele
    Lepore, Luciana
    Grifoni, Alba
    Antinori, Andrea
    Vergori, Alessandra
    Ippolito, Giuseppe
    Cantini, Fabrizio
    Goletti, Delia
    [J]. JOURNAL OF INFECTION, 2021, 82 (04) : 58 - 66
  • [98] Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy
    Prasher, Parteek
    Sharma, Mousmee
    Gunupuru, Ravi
    [J]. DRUG DEVELOPMENT RESEARCH, 2021, 82 (04) : 469 - 473
  • [99] Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
    Qin, Chuan
    Zhou, Luoqi
    Hu, Ziwei
    Zhang, Shuoqi
    Yang, Sheng
    Tao, Yu
    Xie, Cuihong
    Ma, Ke
    Shang, Ke
    Wang, Wei
    Tian, Dai-Shi
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) : 762 - 768
  • [100] Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm
    Rabaan, Ali A.
    Al-Ahmed, Shamsah H.
    Muhammad, Javed
    Khan, Amjad
    Sule, Anupam A.
    Tirupathi, Raghavendra
    Al Mutair, Abbas
    Alhumaid, Saad
    Al-Omari, Awad
    Dhawan, Manish
    Tiwari, Ruchi
    Sharun, Khan
    Mohapatra, Ranjan K.
    Mitra, Saikat
    Bilal, Muhammad
    Alyami, Salem A.
    Bin Emran, Talha
    Moni, Mohammad Ali
    Dhama, Kuldeep
    [J]. VACCINES, 2021, 9 (05)